Blocking KIFC1: How Natural Compounds May Slow Cancer Progression

Greg Howard
7th June, 2025

Blocking KIFC1: How Natural Compounds May Slow Cancer Progression

This pharmacokinetic analysis using the BOILED-Egg model demonstrates that thirty-one propolis-derived compounds exhibit high gastrointestinal absorption and eighteen show blood-brain barrier permeation, validating their potential as drug-like KIFC1 inhibitors.

Image adapted from: Azmi et al. / CC BY (Source)

Key Findings

  • In a study by researchers in Karachi (Pakistan) and Quito (Ecuador), bee propolis compounds were computer-tested for blocking KIFC1, a protein that helps cancer cells survive
  • The simulations showed that compounds like 4’,5,7-trihydroxy-3,6-dimethoxyflavone and 6-methoxykaempferol bind strongly to KIFC1, potentially hampering cancer cell division
  • The computer models confirmed these compounds have drug-like properties and stable interactions, encouraging further lab studies for cancer therapy
[1] Propolis, a resin-like substance produced by bees, has attracted considerable attention for its potential role in cancer therapy. Researchers from Dow University of Health Sciences, University of Karachi, and Universidad San Francisco de Quito conducted a study to explore how compounds derived from propolis might work against a protein called KIFC1. KIFC1 is a type of motor protein that is often found at higher levels in various cancers, where it helps cancer cells divide and survive. Previous research has already hinted at the anticancer potential of propolis[2][3], and this study builds on those findings by focusing on one specific target within cancer cells. In earlier investigations, propolis was shown to have several anticancer effects. For example, studies reported that propolis and its individual components can induce processes like apoptosis—a form of programmed cell death—and cell cycle arrest, which stops cancer cells from multiplying[2][3]. These findings provided a sound basis to explore additional molecular mechanisms through which propolis could help in cancer treatment. The current study used a series of computer-based methods, known as in silico techniques, to evaluate the therapeutic potential of different compounds derived from propolis. Instead of immediately doing complex experiments in a lab, the researchers first turned to computational methods to predict how these compounds might interact with KIFC1. This approach saves time and resources while helping to narrow down the list of candidates for further study in the laboratory. To begin, a 3D library of propolis-related compounds was assembled from previously published literature. Each compound was examined for properties that would make it a good candidate to become a drug. By using tools such as SwissADME and the BOILED-Egg model, the team assessed the compounds for “drug-likeness” and favorable pharmacokinetic properties. Pharmacokinetics refers to how a compound is absorbed, distributed, metabolized, and excreted by the body—factors that are crucial for any successful drug. Once the initial screening was complete, the study focused on five compounds that showed promise in meeting these criteria: kaempferide, luteolin, Izalpinin, 4’,5,7-trihydroxy-3,6-dimethoxyflavone, and 6-methoxykaempferol. The next step involved a process called virtual screening or molecular docking. In molecular docking, scientists simulate how a compound fits into the structure of a target protein. Think of it as testing how well a key fits into a lock. These docking experiments provided estimates of the binding energy (indicated by ΔG) and inhibitory constant (Ki), which are measures indicating how strongly a compound might attach to the protein. Lower values of ΔG and Ki suggest a better and more stable interaction. For instance, the compound kaempferide showed a ΔG of –7.35 kcal/mol and a Ki of 4.12 μM, while other compounds had slightly higher values. These results imply that each compound has the potential to inhibit the action of KIFC1, but some might be more effective than others based on their binding affinities. After the initial docking experiments, the researchers used a method called Cavity Blind (CB) docking. This technique helped them identify specific regions or “pockets” on the KIFC1 protein where these compounds might bind most effectively. Detecting these active residues—the parts of the protein that interact with the compounds—is important because it provides clues about how the inhibition of KIFC1 might occur at the molecular level. To further assess whether these compounds would bind stably over time, the team employed molecular dynamics (MD) simulation. In MD simulations, the behavior of the protein and compound interaction is tracked over a simulated period, in this case 100 nanoseconds. Although 100 nanoseconds is an extremely short period compared to human timescales, it is sufficient to observe how the compound and protein interact and settle into a stable configuration. The results indicated that two compounds, 4’,5,7-trihydroxy-3,6-dimethoxyflavone and 6-methoxykaempferol, exhibited particularly stable binding patterns with KIFC1. MD simulation results showed only minor variations in root-mean-square deviation (RMSD) and fluctuation, parameters that indicate the stability of the compound-protein complex. This study not only confirms earlier observations regarding the therapeutic potential of propolis[2][3] but also expands our understanding by pinpointing KIFC1 as a promising target. The detailed computer experiments suggest that propolis-derived compounds may inhibit this protein, thereby potentially hindering cancer cell survival and division. The researchers conclude that while these findings are promising, further experimental validation—in laboratory (in vitro) and animal (in vivo) studies, and eventually clinical trials—is necessary before these compounds can be considered for real-world cancer therapy. By integrating advanced computational techniques with previous evidence on the anticancer properties of propolis, the study provides a pathway toward more effective cancer treatments. It highlights how traditional natural remedies might be refined and repurposed using modern scientific methods, potentially leading to affordable and viable therapies. Future investigations will need to confirm these computational predictions with experimental data to ensure the safety and effectiveness of these compounds in actual biological systems. The research represents a careful and methodical attempt to bridge natural product research with molecular drug discovery. If subsequent studies confirm these results, propolis-derived compounds may offer new avenues for treating cancers that exhibit high levels of KIFC1, thereby contributing to the broader goal of developing more targeted anticancer therapies.

MedicineBiotechBiochem

References

Main Study

1) KIFC1 inhibition: Exploring the potential of propolis-derived small molecules for targeting cancer progression through in silico analysis

Published 5th June, 2025

https://doi.org/10.1371/journal.pone.0324678

Related Studies

2) Propolis: Antineoplastic Activity, Constituents, and Mechanisms of Action.

https://doi.org/10.2174/1568026623666230321120631

3) Cytotoxic constituents of propolis inducing anticancer effects: a review.

https://doi.org/10.1111/j.2042-7158.2011.01331.x


Related Articles

An unhandled error has occurred. Reload 🗙